Garvan Researchers Say NK Cells Drive MKD Inflammation
Mevalonate kinase deficiency, a rare inflammatory disease, has been misunderstood for 30 years, researchers at the Garvan Institute of Medical Research report in a study published in the journal Immunity.
- Natural killer cells, not macrophages, appear to drive the dangerous inflammation of mevalonate kinase deficiency, overturning three decades of established thinking.
- The defect traps toxic granules inside NK cells, which then flood the body with interferon gamma, a powerful inflammatory signal.
- Existing JAK inhibitors such as baricitinib helped one severely affected infant and could be tested in patients who do not respond to standard therapy.
The condition, known as MKD, causes recurring attacks of high fever, skin rashes, joint pain and abdominal inflammation, and its most severe episodes can be life-threatening. It affects hundreds of children and adults worldwide, though researchers suspect many people with the disorder have never been diagnosed.
For roughly three decades, research into MKD centered on macrophages, the immune cells that coordinate inflammatory defenses, and existing treatments block an inflammatory signal those cells release.
“This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease. In MKD, the primary problem is in NK cells and not in macrophages, as previously believed,” said Dr. Marcia Munoz, Group Leader in the Rogers Lab at Garvan and lead researcher on the study.
Natural killer cells that cannot fire
The Garvan team examined blood samples from people with MKD and studied preclinical models of the disorder. The experiments revealed that natural killer cells, which normally destroy infected cells before an infection spreads, fail to mature properly in MKD patients.
“We found that these immune cells are essentially misfiring,” said Professor Mike Rogers, Lab Head at Garvan and senior author of the study.
“NK cells are loaded with toxic ammunition, stored in granules that are released to kill infected cells. However, in MKD these toxic granules can’t be released from NK cells and remain trapped inside. When an NK cell fails to kill its target, it compensates by shouting for help, pumping out large amounts of interferon gamma – a powerful inflammatory signal. This activates other immune cells and causes the dangerous fever and widespread inflammation seen in patients.”
The consequences extend beyond weakened antiviral defense. When NK cells cannot eliminate their targets, they release large quantities of inflammatory signaling molecules, activating other parts of the immune system and potentially triggering widespread inflammation.
Organ damage traced to failed viral clearance
To test how the cellular defect produces the disease’s severe symptoms, the Garvan researchers worked with Professor Mariapia Degli-Esposti and scientists at Monash University. Using preclinical models, the team linked malfunctioning NK cells to the disorder’s hallmark episodes and showed that when the immune system cannot clear a viral infection, the resulting inflammatory response can cause extensive organ damage.
That result helps explain why a disorder of defective immune defenses also produces extreme inflammation.
Baricitinib tested in one severely affected infant
The discovery has already shaped an experimental treatment. Working with doctors at the Royal Children’s Hospital in Melbourne, the researchers explored whether baricitinib, a JAK inhibitor already approved for rheumatoid arthritis and eczema, could reduce the excessive inflammatory signaling tied to MKD. JAK inhibitors interfere with signaling pathways the immune system uses, including responses to interferon gamma.
Doctors added baricitinib to the infant’s existing regimen and subsequently observed an improvement in the child’s condition.
Because the proposed treatment uses existing medications, it may be faster to test in patients.
“This study has revealed a new target for this inflammatory disorder and sets the scene for future clinical studies to explore the use of JAK inhibitors or other drugs to neutralize interferon gamma in patients with MKD,” said Rogers. “This could lead to a targeted treatment that hasn’t been tried before.”
A family of related disorders
The implications may reach beyond MKD. Researchers have introduced the term “prenylopathies” for a family of genetic disorders involving the same metabolic pathway affected in MKD. Early findings suggest these related diseases may share a similar underlying problem: NK cells that fail to function properly and instead generate excessive inflammatory signals.
If further studies confirm the connection, scientists may be able to identify common disease mechanisms and develop more targeted approaches to diagnosis and treatment across multiple disorders.
“Confirming this link could help end the diagnostic odyssey many patients endure for years or even decades before receiving effective treatment,” said Rogers.
The researchers describe their findings as a foundation for future clinical studies of JAK inhibitors and other drugs that block interferon gamma activity, particularly in patients who have not benefited from standard treatments.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.